US10131667, Example 175;11-(2,6-difluoro-3,5-dimethoxyphenyl)-13-[1-(2,2-difluoroethyl)pyrazol-4-yl]-4,5,7,11,13-pentazatricyclo[7.4.0.02,6]trideca-1,3,6,8-tetraen-12-one
CAS
1513858-26-8
化学式
C21H17F4N7O3
mdl
——
分子量
491.405
InChiKey
NNQDXZIFZXDKKV-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
物化性质
计算性质
ADMET
安全信息
SDS
制备方法与用途
上下游信息
反应信息
文献信息
表征谱图
同类化合物
相关功能分类
相关结构分类
计算性质
辛醇/水分配系数(LogP):
2.1
重原子数:
35
可旋转键数:
6
环数:
5.0
sp3杂化的碳原子比例:
0.24
拓扑面积:
101
氢给体数:
1
氢受体数:
10
文献信息
SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS
申请人:Incyte Corporation
公开号:US20170137424A1
公开(公告)日:2017-05-18
The present invention relates to tricyclic compounds, and pharmaceutical compositions of the same, that are inhibitors of one or more FGFR enzymes and are useful in the treatment of FGFR-associated diseases such as cancer.
Substituted tricyclic compounds as FGFR inhibitors
申请人:Incyte Corporation
公开号:US11053246B2
公开(公告)日:2021-07-06
The present invention relates to tricyclic compounds, and pharmaceutical compositions of the same, that are inhibitors of one or more FGFR enzymes and are useful in the treatment of FGFR-associated diseases such as cancer.
[EN] SUBSTITUTED TRICYCLIC COMPOUNDS AS FGFR INHIBITORS<br/>[FR] COMPOSÉS TRICYCLIQUES SUBSTITUÉS UTILISÉS COMME INHIBITEURS DE FGFR
申请人:INCYTE CORP
公开号:WO2014007951A2
公开(公告)日:2014-01-09
The present invention relates to tricyclic compounds, and pharmaceutical compositions of the same, that are inhibitors of one or more FGFR enzymes and are useful in the treatment of FGFR-associated diseases such as cancer.